www.alk.net
  • Your allergy
    • What is allergy
      • House dust mite allergy
      • Pollen allergy
      • Living with allergy
      • Socio-economic impact
    • What is allergic asthma
    • How is allergy diagnosed
    • Treating allergy
  • Our solutions
    • Consumer healthcare
    • Diagnostics
    • Allergy vaccines
      • Production
    • Emergency medicine
  • Our science
    • Scientific focus
    • Science & technology
    • Pipeline
    • Digital innovation
    • Clinical data sharing
    • Collaboration & partnerships
    • Healthcare Professionals
      • Allergy Immunotherapy
      • Reweal
      • Clinical trials
      • Webinars
      • The Henning Lowenstein Research Award
  • Our company
    • Press
    • Our strategy
    • Our leadership
    • Our history
    • Corporate governance
  • Sustainability
  • Investors
    • Overview
    • Financial reporting
      • Risk management
      • Reporting standards
      • Auditors
    • Governance
      • Executive Leadership Team
      • Board of Directors
    • News & Events
      • Company Releases
      • Company releases (DK)
      • Webcasts & presentations
      • Investor calendar
      • Capital Markets Day 2024
    • The Share
      • Dividend history
      • Analyst coverage
      • Analyst estimates
      • Shareholder information
      • Authorizations
    • Contact IR
    • Annual general meeting
      • Annual general meeting (DK)
    • Capital Markets Day 2024
  • Careers
    • Working at ALK
    • Vacant positions
    • Cultural Beliefs
  • Select country
Search

News release

Links: 
Company Releases
Company releases (DK)
Webcasts & presentations
Investor calendar
Capital Markets Day 2024

« Back

Report on Management's transactions with ALK-Abelló A/S B-shares and associated securities

October 01, 2014

PDF Version

Supporting Materials:
FM_32_14UK_01102014.pdf

 

 

Copenhagen, 2014-10-01 11:42 CEST (GLOBE NEWSWIRE) --  

ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF): Pursuant to section 28(a) of the Danish Securities Trading Act, ALK-Abelló A/S shall report the following transactions based on the allotments of conditional shares which ALK has granted to the company's Board of Management in accordance with the incentive payments guidelines adopted at the company's annual general meeting on 12 March 2014:

NameHelle Skov
ReasonMember of the Board of Management
IssuerALK-Abelló A/S
ISIN codeDK0060027142
TypeConditional shares
TransactionAllotment
Allotment date1 October 2014
MarketNASDAQ OMX Copenhagen A/S
Number600
Market valueDKK 427,560

 

ALK-Abelló A/S
 

Contact: Steen Riisgaard, Chairman of the Board of Directors, tel. +45 4574 7576

 

  • Email Alerts

    Email Alerts

  • Downloads

    Downloads

  • RSS

    RSS

  • Print

    Print

  • Share

    Share

  • English

    English

  • Search

    Search




Select Country Menu

  • Change Country

Quick Links

  • Contact us
  • News
  • Media
  • Vacant jobs
  • Products

ALK Footer Copyright Text

ALK-Abelló A/S ∙ Bøge Allé 6 ∙ DK-2970 Hørsholm ∙ Denmark ∙ CVR no. 63717916 ∙ T +45 45 74 75 76 Legal disclaimer © ALK ∙ All rights reserved